Select Page
Dimitrios Papadopoulos
Associate Professor, Neurology
d.papadopoulos@euc.ac.cy
22559410
Academic Qualifications
Qualification Year Awarding Institution Department
PhD 2003 Imperial College London Cellular and Molecular Neuroscience
FEBN 2012 Union of European Medical Specialties (UEMS) European Board of Neurology
DIC 2004 Imperial College London Cellular and Molecular Neuroscience
MD 1998 National and Kapodistrian University of Athens School of Medicine
Employment History
 
Period of employment Employer Location Position
From To
2016 To date Hellenic Pasteur Institute Athens Research Associate
2014 To date National and Kapodistrian University of Athens Athens Research Associate
2006 2008 Imperial College London London Research Fellow
Publications
Year Title Other authors Journal and Publisher / Conference Vol. Pages
2022 Automated characterisation of microglia in ageing mice using image processing and supervised machine learning algorithms. Choi S, Hill D, Guo L, Nicholas R, Papadopoulos D, Cordeiro MF. Science Reports 12 1806
2022 Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression. Papadopoulos D, Gklinos P, Psarros G, Drellia K, Delicha EM, Friede T, Mitsikostas DD, Nicholas RS. Journal of Neurology e-pub ahead of print
2021 Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. Stanulović V, Hodolic M, Mitsikostas DD, Papadopoulos D. British Journal of Clinical Pharmacology 88 551
2021 Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Cephalalgia 41 851
2021 Monoclonal Antibodies as Neurological Therapeutics. Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. Pharmaceuticals 14 92
2021 A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. Mitsikostas DD, Doskas T, Gkatzonis S, Fakas N, Maltezou M, Papadopoulos D, Gourgioti R, Mitsias P. Advances in Therapeutics 38 1536
2020 Aging, Cellular Senescence, and Progressive Multiple Sclerosis. Papadopoulos D, Magliozzi R, Mitsikostas DD, Gorgoulis VG, Nicholas RS. Frontiers in Cellular Neuroscience 14 178
2012 TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE Tsakiri N, Papadopoulos D, Denis MC, Mitsikostas DD, Kollias G. European Journal of Immunology 42 403
2009 Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Papadopoulos D, Dukes S, Patel R, Nicholas R, Vora A, Reynolds R. Brain Pathology 19 238
2006 Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. Papadopoulos D, Ewans L, Pham-Dinh D, Knott J, Reynolds R. Molecular Cellular Neuroscience 31 597
Exhibitions
Research Projects
Date Title Funded by Project Role*
2018-2019 Is cellular senescence responsible for disability progression in progressive multiple sclerosis? Multiple society of Great Britain and Northern Ireland Co-investigator
2017-2019 The role of cellular senescence and ageing in disability progression in multiple sclerosis Multiple Sclerosis Trials Collaboration, UK Principal investigator
2020-to date A non-interventional prospective observational study to assess the effect of treatment with dimethyl-fumarate on the change of cervical spinal cord load and cervical cord atrophy in Multiple Sclerosis patients Genesis Pharma Principal investigator
2017-2019 Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis (FAMILY). A phase IV, non-interventional, observational multi-centre study. Genesis Pharma Principal Investigator
2006-2008 A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) in Patients With Relapsing-remitting Multiple Sclerosis. Novartis Investigator
1999-2003 Axonal loss and neurodegeneration in the Mog-induced EAE model of multiple sclerosis NATO scholarship PhD studentship
Academic Consulting Services/Councils/Boards/Editorial Committees
Awards/International Recognition
Other Achievements